Business

Savara has announced that the European Patent Office and the Australian Patent Office have issued new patents covering Molbreevi molgramostim inhalation solution. Both the European patent, No.4121000, and the Australian patent, No. 62/990,810, protect Molbreevi… Read more . . .

Eli Lilly and Company has agreed to pay approximately $2.8 billion up front and up to an additional $1 billion in milestone payments for pyschedelics developer AtaiBeckley, the companies said. AtaiBeckley’s lead candidate is BPL-003… Read more . . .

According to Sino Biopharmaceutical, AstraZeneca will pay $200 million up front and a total of up to $1.9 billion for the development, manufacturing, and commercialization rights to Sino Biopharm’s TQC3721 inhaled PDE3/4 inhibitor outside of… Read more . . .

The Australian Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative is providing over AU $15 million to Atisama Therapeutics (formerly Rage Bio) and Monash University to support continued development of RB042 inhaled… Read more . . .

Canadian biotech Zymeworks has agreed to pay $17 per share, a total of approximately $929 million, to acquire Theravance Biopharma, the companies have announced. The deal, which is subject to approval by Theravance shareholders, is… Read more . . .

The European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio are among those contributing to a €40 million financing to support development of Leyden Laboratories’ antiviral nasal sprays the company said. Since the beginning of… Read more . . .

University of St Andrews spin out Pneumagen has reorganized as a US-based company called NorthLinks Bio, the company said, though research will continue in Scotland. Pneumagen CEO Douglas Thomson has joined the board of the… Read more . . .